Lonidamine

Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM) . Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis[1][2][3].

Product Specifications

CAS Number

[50264-69-2]

Product Name Alternative

AF-1890; Diclondazolic Acid; DICA

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Hexokinase; Mitochondrial Metabolism; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/lonidamine.html

Purity

99.91

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(C1=NN(CC2=CC=C(Cl)C=C2Cl)C3=C1C=CC=C3)O

Molecular Formula

C15H10Cl2N2O2

Molecular Weight

321.16

Precautions

H302, H315, H319, H335

References & Citations

[1]Nancolas B, et al. The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters. Biochem J. 2016 Apr 1;473 (7) :929-36. |[2]Ilya A Shutkov, et al. Ru (III) Complexes with Lonidamine-Modified Ligands. Int J Mol Sci. 2021 Dec 15;22 (24) :13468. |[3]Xueqian Yin, et al. Hexokinase 2 couples glycolysis with the profibrotic actions of TGF-β. Sci Signal. 2019 Dec 17;12 (612) :eaax4067. |[4]Gang Cheng, et al. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019 May 17;10 (1) :2205.